RANI
ACHAT TOTAL: 71 000 titres (~50 033,00 $ US)
- Insiders
- IMRAN MIR A, Imran Talat
- Total bought
- $50,033
- Total sold
- —
- Last activity
- 2026-07-21
- Last synced
-
2026-07-29 15:28:58
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-07-29
RANI presents a genuine event-driven catalyst — a timely insider cluster buy following positive Phase 1a RT-114 obesity data (+150% bioavailability vs.
The first sentence of the analysis written for RANI on 2026-07-29 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 44.9% | 100.0% | 0.0% | 0.0% | 100.0% | |
| Ebit Margin | -2330.6% | -5014.7% | 0.0% | 0.0% | -1935.3% | |
| Ebitda Margin | -2275.5% | -4914.7% | 0.0% | 0.0% | -1917.0% | |
| Operating Profit Margin | -2346.0% | -5186.2% | 0.0% | 0.0% | -1899.1% | |
| Pretax Profit Margin | -2507.7% | -2920.0% | 0.0% | 0.0% | -1952.4% | |
| Continuous Operations Profit Margin | -2507.7% | -5504.3% | 0.0% | 0.0% | -1953.9% | |
| Net Profit Margin | -1817.1% | -2920.0% | 0.0% | 0.0% | -306.6% | |
| Bottom Line Profit Margin | -1817.1% | -2920.0% | 0.0% | 0.0% | -306.6% | |
| Current Ratio | 4.209 | 1.495 | 6.365 | 20.960 | 45.301 | |
| Quick Ratio | 4.209 | 1.495 | 6.365 | 20.960 | 45.301 | |
| Solvency Ratio | -1.682 | -0.875 | -1.021 | -0.883 | -2.967 | |
| Cash Ratio | 1.470 | 0.189 | 0.734 | 5.609 | 44.490 | |
| Price To Earnings Ratio | -3.000 | -1.305 | -2.496 | -4.609 | -38.929 | |
| Price To Earnings Growth Ratio | 0.053 | 0.062 | -0.639 | -0.023 | 0.770 | |
| Forward Price To Earnings Growth Ratio | 0.053 | 0.062 | -0.639 | -0.023 | 0.770 | |
| Price To Book Ratio | 2.705 | 19.584 | 6.581 | 3.813 | 6.736 | |
| Price To Sales Ratio | 54.676 | 37.950 | 0.000 | 0.000 | 117.549 | |
| Price To Free Cash Flow Ratio | -4.749 | -1.091 | -1.614 | -2.919 | -9.752 | |
| Price To Operating Cash Flow Ratio | -4.771 | -1.099 | -1.653 | -3.021 | -9.905 | |
| Debt To Assets Ratio | 0.074 | 0.811 | 0.520 | 0.280 | 0.000 | |
| Debt To Equity Ratio | 0.131 | 14.914 | 2.339 | 0.820 | 0.000 | |
| Debt To Capital Ratio | 0.116 | 0.937 | 0.701 | 0.450 | 0.000 | |
| Long Term Debt To Capital Ratio | 0.076 | 0.828 | 0.656 | 0.442 | 0.000 | |
| Financial Leverage Ratio | 1.776 | 18.391 | 4.501 | 2.931 | 2.620 | |
| Working Capital Turnover Ratio | 0.065 | 0.039 | 0.000 | 0.000 | 0.029 | |
| Operating Cash Flow Ratio | -1.477 | -1.785 | -6.413 | -9.660 | -12.214 | |
| Operating Cash Flow Sales Ratio | -11.460 | -34.529 | 0.000 | 0.000 | -11.868 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.005 | 1.008 | 1.024 | 1.035 | 1.016 | |
| Debt Service Coverage Ratio | -12.853 | -3.848 | -6.209 | -57.633 | -111.856 | |
| Interest Coverage Ratio | -13.251 | -10.593 | -12.999 | -59.245 | -110.727 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | -2.366 | -10.463 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -4.334 | -1.195 | -1.702 | -1.540 | 0.000 | |
| Capital Expenditure Coverage Ratio | -212.659 | -132.448 | -41.689 | -28.731 | -63.725 | |
| Dividend Paid And Capex Coverage Ratio | -212.659 | -132.448 | -41.689 | -28.731 | -63.725 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -2.018 | -1.286 | -1.757 | -2.331 | -3.877 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 44.9% | ▼-55.1% | ▼-4.1% |
| Ebit Margin | -2330.6% | ▲2684.1% | ▼-474.5% |
| Ebitda Margin | -2275.5% | ▲2639.2% | ▼-454.1% |
| Operating Profit Margin | -2346.0% | ▲2840.2% | ▼-459.7% |
| Pretax Profit Margin | -2507.7% | ▲412.4% | ▼-1031.6% |
| Continuous Operations Profit Margin | -2507.7% | ▲2996.6% | ▼-514.5% |
| Net Profit Margin | -1817.1% | ▲1103.0% | ▼-808.3% |
| Bottom Line Profit Margin | -1817.1% | ▲1103.0% | ▼-808.3% |
| Current Ratio | 4.209 | ▲2.713 | ▼-11.457 |
| Quick Ratio | 4.209 | ▲2.713 | ▼-11.457 |
| Solvency Ratio | -1.682 | ▼-0.807 | ▼-0.196 |
| Cash Ratio | 1.470 | ▲1.280 | ▼-9.029 |
| Price To Earnings Ratio | -3.000 | ▼-1.695 | ▲7.068 |
| Price To Earnings Growth Ratio | 0.052 | ▼-0.009 | ▲0.008 |
| Forward Price To Earnings Growth Ratio | 0.052 | ▼-0.009 | ▲0.008 |
| Price To Book Ratio | 2.705 | ▼-16.880 | ▼-5.179 |
| Price To Sales Ratio | 54.676 | ▲16.727 | ▲12.641 |
| Price To Free Cash Flow Ratio | -4.749 | ▼-3.658 | ▼-0.724 |
| Price To Operating Cash Flow Ratio | -4.771 | ▼-3.672 | ▼-0.681 |
| Debt To Assets Ratio | 0.074 | ▼-0.737 | ▼-0.263 |
| Debt To Equity Ratio | 0.131 | ▼-14.783 | ▼-3.510 |
| Debt To Capital Ratio | 0.116 | ▼-0.822 | ▼-0.325 |
| Long Term Debt To Capital Ratio | 0.076 | ▼-0.752 | ▼-0.324 |
| Financial Leverage Ratio | 1.776 | ▼-16.615 | ▼-4.268 |
| Working Capital Turnover Ratio | 0.065 | ▲0.026 | ▲0.038 |
| Operating Cash Flow Ratio | -1.477 | ▲0.307 | ▲4.833 |
| Operating Cash Flow Sales Ratio | -11.460 | ▲23.069 | ▲0.112 |
| Free Cash Flow Operating Cash Flow Ratio | 1.005 | ▼-0.003 | ▼-0.013 |
| Debt Service Coverage Ratio | -12.853 | ▼-9.005 | ▲25.627 |
| Interest Coverage Ratio | -13.252 | ▼-2.659 | ▲28.112 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | ▲2.366 | ▲2.566 |
| Operating Cash Flow Coverage Ratio | -4.334 | ▼-3.139 | ▼-2.580 |
| Capital Expenditure Coverage Ratio | -212.659 | ▼-80.211 | ▼-116.809 |
| Dividend Paid And Capex Coverage Ratio | -212.659 | ▼-80.211 | ▼-116.809 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -2.018 | ▼-0.732 | ▲0.236 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $89.3M | $39.0M | $84.7M | $140.5M | $319.4M | |
| Enterprise value | $75.0M | $65.0M | $108.9M | $143.7M | $201.9M | |
| EV / Sales | 45.92x | 63.19x | 0.00x | 0.00x | 74.32x | |
| EV / Op. cash flow | -4.01x | -1.83x | -2.13x | -3.09x | -6.26x | |
| EV / Free cash flow | -3.99x | -1.82x | -2.08x | -2.99x | -6.17x | |
| EV / EBITDA | -2.02x | -1.29x | -1.76x | -2.33x | -3.88x | |
| Net debt / EBITDA | 0.39x | -0.51x | -0.39x | -0.05x | 2.25x | |
| Current ratio | 4.21x | 1.50x | 6.37x | 20.96x | 45.30x | |
| Income quality | 0.63x | 0.63x | 1.51x | 0.73x | 3.87x | |
| Graham net-net | $1 | -$0 | $1 | $3 | $6 | |
| Tax burden | 72.5% | 100.0% | 50.0% | 48.3% | 15.7% | |
| Interest burden | 107.6% | 58.2% | 108.1% | 101.7% | 100.9% | |
| Working capital | $40.7M | $9.9M | $42.9M | $96.1M | $117.0M | |
| Invested capital | $45.7M | $16.5M | $49.7M | $103.2M | $121.6M | |
| Return on assets | -50.6% | -81.9% | -58.7% | -28.3% | -6.7% | |
| Operating ROA | -80.4% | -112.8% | -79.7% | -54.6% | -50.7% | |
| Return on tangible assets | -50.6% | -81.9% | -58.7% | -28.3% | -6.7% | |
| Return on equity | -89.9% | -1506.9% | -264.0% | -83.0% | -17.6% | |
| Return on invested capital | -80.6% | -160.6% | -119.0% | -60.9% | -42.4% | |
| Return on capital employed | -83.4% | -318.4% | -132.4% | -61.5% | -42.4% | |
| Earnings yield | -33.2% | -76.9% | -40.1% | -21.8% | -2.6% | |
| Free cash flow yield | -21.1% | -91.7% | -62.0% | -34.3% | -10.3% | |
| Capex / Op. cash flow | -0.5% | -0.8% | -2.4% | -3.5% | -1.6% | |
| Capex / Depreciation | 9.8% | 26.1% | 149.5% | 295.4% | 101.8% | |
| Capex / Sales | 5.4% | 26.1% | 0.0% | 0.0% | 18.6% | |
| SG&A / Sales | 1208.7% | 2329.4% | 0.0% | 0.0% | 1024.4% | |
| R&D / Sales | 1237.3% | 2595.5% | 0.0% | 0.0% | 974.7% | |
| Stock comp / Sales | 722.5% | 1559.4% | 0.0% | 0.0% | 831.6% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 456d | 152d | 0d | 0d | 0d | |
| Days payables outstanding | 125d | 0d | 288d | 0d | 0d | |
| Operating cycle | 456d | 152d | 0d | 0d | 0d | |
| Cash conversion cycle | 331d | 152d | -288d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+128.9%EV / Sales ▼-27.3%EV / EBITDA ▼-57.0%EV / Op. cash flow ▼-2.177Earnings yield ▲+0.437
Profitability
Return on equity ▲+14.170Return on assets ▲+0.313Return on invested capital ▲+0.800Return on capital employed ▲+2.351Operating ROA ▲+0.323Income quality ▲+0.003Tax burden ▼-0.275
Efficiency
Days sales outstanding ▲+304.453Days payables outstanding n/aOperating cycle ▲+304.453Cash conversion cycle ▲+179.136Capex / Sales ▼-0.207R&D / Sales ▼-13.582
Balance-sheet strength
Current ratio ▲+2.713Net debt / EBITDA ▲+0.898Working capital ▲+30799000.000Invested capital ▲+29209000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▼-72.0%EV / Sales ▼-38.2%EV / EBITDA ▲+47.9%EV / Op. cash flow ▲+2.255Earnings yield ▼-0.306
Profitability
Return on equity ▼-0.723Return on assets ▼-0.439Return on invested capital ▼-0.381Return on capital employed ▼-0.409Operating ROA ▼-0.298Income quality ▼-3.240Tax burden ▲+0.568
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales ▼-0.132R&D / Sales ▲+2.626
Balance-sheet strength
Current ratio ▼-41.092Net debt / EBITDA ▼-1.870Working capital ▼-76303000.000Invested capital ▼-75861000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-07-20 Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SAN JOSE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”; “Rani” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported that it granted an equity award in the form of a stock option to purchase 2,000,000 shares of Rani Class A common stock to Nicholas Maestas, Rani's new Chief Financial Officer, as an inducement material to his acceptance of employment with Rani.
- 2026-07-15 Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of PG-102 No adverse events attributed to RaniPill Capsule; treatment-related adverse events were mild and consistent with the GLP-1/GLP-2 agonist class of therapeutics Phase 1a study expanded with an additional cohort to further define the oral-to-subcutaneous pharmacokinetic relationship ahead of a planned Phase 1b repeat-dose study in patients with obesity SAN JOSE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today reported positive initial data from the ongoing Phase 1 study of RT-114, an orally administered RaniPill® Capsule delivering PG-102, a GLP-1/GLP-2 dual agonist being developed by ProGen Co., Ltd.
- 2026-07-09 Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates ~ Collaboration will leverage the RaniPill® platform to explore oral delivery of PegBio's proprietary portfolio of novel obesity and metabolic disease molecules ~
- 2026-06-29 Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer SAN JOSE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”; “Rani” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Nicholas Maestas as Chief Financial Officer, effective immediately.
- 2026-05-26 Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules SAN JOSE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a securities purchase agreement led by a sovereign wealth fund, along with other new and existing healthcare-focused funds for the purchase and sale of 12,476,637 shares of Rani Therapeutics' Class A common stock at a purchase price of $1.07 per share and pre-funded warrants to purchase 6,214,953 shares of Class A common stock at a purchase price of $1.0699 per pre-funded warrant in a registered direct offering priced at-the-market under Nasdaq rules.
- 2026-05-15 Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition - Continued advancement of the ongoing Phase 1 study of RT-114 via RaniPill® for the treatment of obesity in collaboration with ProGen –
- 2026-05-12 Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference SAN JOSE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company's management team will participate in the upcoming H.C.